EGFR-targeting tyrosine kinase inhibitors (TKIs) have been commonly used to target and treat EGFR-positive non-small cell lung carcinoma (NSCLC) with differential sensitivity of TKIs to different EGFR mutations [9]. Here, EGFR is linked to non-small cell lung carcinoma.